Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2023-03-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
华英证券有限责任公司关于深圳信立泰药业股份有限公司2022年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a securities company regarding the storage and use of raised funds by Shenzhen Salubris Pharmaceuticals Co., Ltd. for the year 2022. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed financial data on fundraising amounts, usage, balances, and compliance with regulations. The document is not an annual report or earnings release but a specialized audit or verification report focused on fundraising and capital usage. It contains substantive financial data and analysis related to fundraising management and usage, consistent with an Audit Report / Information filing rather than a general regulatory announcement or report publication announcement. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2022
2023-03-28 Chinese
2022年度独立董事述职报告（王学恭）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2022" from Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the independent director's attendance at board meetings and shareholders' meetings, opinions on various company matters, work on board committees, supervision of internal controls and information disclosure, and other duties performed during the year 2022. The document is a narrative report on the independent director's activities and opinions rather than a financial report or announcement. It does not contain financial statements or audit results, nor is it a notice or announcement of voting results or management changes. It is a formal report by an independent director on their duties and observations for the year, which fits best under the category of Board/Management Information (MANG). The document length is 2755 characters, which is relatively short but contains substantive content about board activities and management oversight, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2023-03-28 Chinese
董事会关于分拆所属子公司上市董事会决议日前股票价格波动情况的说明
Regulatory Filings Classification · 95% confidence The document is a board announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the stock price fluctuations before the board resolution on the spin-off and listing of its subsidiary. It references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The content focuses on explaining stock price movements and confirming no abnormal fluctuations before the board decision. It is not a full financial report, earnings release, or management discussion, but a regulatory disclosure related to a board decision and stock price behavior. This fits best under Regulatory Filings (RNS) as it is a compliance-related announcement that does not fit other specific categories.
2023-03-28 Chinese
2022年度独立董事述职报告（刘来平）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2022" from Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters, participation in committees, supervision of internal controls, and other governance-related activities during the year 2022. The content focuses on the director's duties, oversight, and governance role rather than financial results or audit opinions. It is a report by an independent director on their work and governance oversight, which fits best under Board/Management Information (MANG) as it relates to management and board activities and changes. The document is not an annual report, audit report, or earnings release, nor is it a proxy or voting announcement. Therefore, the classification is MANG with high confidence.
2023-03-28 Chinese
2022年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2022 Annual Supervisory Board Work Report" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the supervisory board's activities throughout 2022, including meetings held, oversight of financials, internal controls, compliance with laws and regulations, and supervision of various company operations. It references the review and supervision of quarterly reports, half-year reports, and the annual report for 2022, but the document itself is a supervisory board report summarizing oversight activities rather than the financial reports themselves. The document length is 4254 characters, which is relatively short but contains substantive content about supervisory activities and oversight rather than just an announcement. This type of document is best classified as an Audit Report / Information (AR) because it focuses on supervisory and audit-related oversight, internal controls, and compliance, rather than being the full annual report or a simple announcement. FY 2022
2023-03-28 Chinese
独立董事对担保等事项的独立意见
Governance Information Classification · 95% confidence The document is titled as an independent directors' opinion on various company matters for the year 2022, including profit distribution, remuneration, internal control evaluation, audit firm reappointment, use of idle funds, accounting policy changes, and a proposed spin-off listing. It references compliance with Chinese securities laws and regulations, and it provides detailed independent opinions on these corporate governance and financial matters. The document is not a full annual report or audit report but rather an independent directors' statement on specific company issues, including approval of proposals and opinions on governance and financial practices. This type of document aligns with a Governance Information (CGR) filing, as it details governance-related opinions and compliance with regulatory requirements. The document length (5310 characters) and content confirm it is a detailed governance-related report rather than a brief announcement or a full financial report.
2023-03-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.